Professur für Dermatologie

Secukinumab Treatment of moderate to severe Plaque Psoriasis in the clinical Routine Care: Baseline Data from the PROSPECT Study on Psoriasis Pre-treatment (2017) Von Kiedrowski R, Korber A, Kraehn-Senftleben G, Sticherling M, Lange L, Bachhuber T, Kasparek TR, et al. Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without previous Systemic Therapy for Improvement of Skin Symptoms: PASI and IGA mod. 2011-Results of the PRIME Study (2017) Reich K, Mrowietz U, Augustin M, Thaci D, Kneidl J, Hentschke C, Simang M, et al. Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without prior System Therapy with respect to the Improvement of quality of life: DLQI and SF-36 Results of the PRIME Study (2017) Augustin M, Thaci D, Reich K, Mrowietz U, Kneidl J, Hentschke C, Simang M, et al. Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without prior System Therapy with regard to compatibility-related Therapeutic Adherence: Safety Results of the PRIME Study (2017) Mrowietz U, Augustin M, Thaci D, Reich K, Kneidl J, Hentschke C, Simang M, et al. Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis with without previous Systemic Therapy for Improvement of Nail Symptoms: NAPSI Results PRIME Study (2017) Thaci D, Reich K, Mrowietz U, Augustin M, Kneidl J, Hentschke C, Simang M, et al. Conference contribution Psoriasis - Occurrence and Reality: Disease of the Psoriasis Group (2017) Leupolz S, Sticherling M Conference contribution Psoriasis vulgaris as Manifestation of Immune Reconstitution in Patients with Hepatitis C under Treatment with Ledipasvir/Sofosbuvir (2017) Heppt F, Sticherling M Conference contribution Lungs Ailment - other Comorbidity of the Psoriasis? (2017) Moreira A, Sticherling M Conference contribution PASI <= 2 corresponds to PASI 90, irrespective of baseline severity: A post-hoc analysis of the PRIME-study (2017) Reich K, Sieder C, Bachhuber T, Melzer N, Sticherling M Conference contribution Psoriasis in children: a single-centre analysis (2017) Heppt F, Raap J, Sticherling M Conference contribution